What topics does this cannabis study cover?

This study covers research on: Addiction, Anxiety, Neuroprotection, Mental Health, Endocannabinoid.

Where was this research published?

Published in Cureus on June 1, 2026.

Addiction Anxiety Neuroprotection Mental Health Endocannabinoid

How genes shape addiction differently across substances and conditions

Cross-Disorder Pruning-Plasticity-Aging Architecture in Substance Use Disorders and Anxiety: Transcriptome-Wide Association Insights and Mechanistic Synthesis.

Cureus • June 1, 2026 • Review • Moderately Relevant

🤖

AI Summary

This research synthesizes findings from multiple transcriptome-wide association studies (TWAS) to reveal how genetic factors shape substance use disorders and anxiety through three distinct biological mechanisms: pruning (immune-related brain cell refinement), plasticity (flexibility in neural connections), and aging. Rather than viewing addiction as a single spectrum, researchers found that different patterns of substance use involve fundamentally different brain processes. Lighter opioid use and some lower-risk alcohol profiles involve immune system changes, while heavier opioid dependence, cannabis use disorder, and severe alcohol misuse activate plasticity pathways that remodel brain reward circuits through mechanisms like AMPK-mTOR signaling and mitochondrial energy production.

The study identifies a striking contrast between cannabis use disorder and anxiety: cannabis use disorder shows activation of TREM2-positive immune responses, whereas anxiety involves SARM1-linked axonal stress and inflammatory-apoptotic pathways. This distinction suggests that the same brain systems can be affected very differently depending on whether someone develops addictive patterns versus anxiety symptoms. The research also reveals that aging biology doesn't uniformly increase addiction risk but rather shows branch-specific effects through NAD/sirtuin stress-response systems. Importantly, this is a synthesis of genetic predictions rather than direct measurements of patient brain tissue, making the findings hypothesis-generating rather than definitively proven.

While this research doesn't focus specifically on cannabis as a therapeutic agent, it provides crucial insight into why some individuals develop cannabis use disorder while others don't, and how cannabis-related biological changes differ from other psychiatric conditions. Understanding these genetic and molecular mechanisms could eventually guide personalized prevention and treatment approaches, though the authors emphasize that these findings require validation through further colocalization studies, cell-type analysis, and functional experiments before clinical application.

📄 Original Abstract

Substance use disorders and anxiety are clinically heterogeneous, and broad case-control genetic designs can obscure stage- and subtype-specific biology. A recent series of five transcriptome-wide association study (TWAS) preprints by Cheung examined opioid exposure versus dependence progression, alcohol misuse latent classes, cannabis use disorder, anxiety, and aging-related gene sets. Together, these studies suggest a cross-disorder architecture organized around a Pruning-Plasticity-Aging axis. This synthesis is narrative and hypothesis-generating, because the primary cross-disorder evidence comes from preprints and genetically predicted expression rather than measured patient expression. In this model, liability is not distributed along a single psychiatric-risk continuum. Instead, opioid exposure and some lower-risk or internalizing alcohol profiles appear to involve altered neuroimmune pruning and glial-synaptic refinement, whereas opioid dependence progression, heavier alcohol classes, broad-risk alcohol profiles, and cannabis use disorder show stronger involvement of glutamatergic plasticity, presynaptic adaptation, reward-circuit remodeling, AMP-activated protein kinase-mechanistic target of rapamycin (AMPK-mTOR) nutrient sensing, mitochondrial bioenergetics, and selected nicotinamide adenine dinucleotide (NAD)/sirtuin stress-response branches. Anxiety diverges by loading more strongly on inflammatory-apoptotic signaling, complement/sterile alpha and toll/interleukin receptor motif-containing protein 1 (SARM1)-linked axonal stress, and mitochondrial NAD-stress programmes. The most promising findings include stage-specific opposition in opioid TWAS profiles, latent-class plasticity inversion in alcohol misuse, a triggering receptor expressed on myeloid cells 2 (TREM2)-positive cannabis use disorder profile contrasted with a SARM1/complement C1q C chain (C1QC)-positive anxiety profile, and branch-specific rather than global aging biology. This review synthesizes these findings; places them in established addiction, neuroimmune, and aging biology; and outlines validation priorities for colocalization, fine-mapping, cell-type resolution, and functional testing.